Outcomes of advanced and recurrent cervical cancer treated with cisplatin and generic topotecan: Retrospective analysis in a tertiary care hospital in Thailand

Journal of Gynecologic Oncology

Volumn 21, Issue 4, 2010, Pages 237-240

  Suprasert, Prapaporn ^a   Charoenkwan, Kittipat ^a   Cheewakriangkrai, Chalong ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Advance; Cervical cancer; Cisplatin; Recurrence; Topotecan

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERCEPTION DEAFNESS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THAILAND; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

EID: 79952398216     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2010.21.4.237     Document Type: Article

References (8)

1. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985; 3: 1079-85. (Pubitemid 15004828)
2. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: 4626-33. (Pubitemid 46224065)
3. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14. (Pubitemid 11167383)
4. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, ver. 3.0 [Internet]. Bethesda (MD): NIH; 2006 [cited 2010 Sep 20]. Available from: . nih.gov/protocol Development/electronic-applications/ docs/ ctcaev3.pdf.
5. Randall-Whitis LM, Monk BJ. Topotecan in the management of cervical cancer. Expert Opin Pharmacother 2007; 8: 227-36. (Pubitemid 46206624)
6. Belozerov VE, Van Meir EG. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 2005; 16: 901-9. (Pubitemid 41416080)
7. Fiorica JV, Blessing JA, Puneky LV, Secord AA, Hoffman JS, Yamada SD, et al. A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2009; 115: 285-9.
8. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009; 27: 4649-55.